RUBEDO LIFE SCIENCES - About the company
RUBEDO LIFE SCIENCES is a series A company based in Sunnyvale (United States), founded in 2018 by Marco Quarta, Mark Gallop and Julian Klein. It operates as a Developer of therapeutics for age-related diseases. RUBEDO LIFE SCIENCES has raised $52M in funding from Khosla Ventures and Ahren. The company has 161 active competitors, including 49 funded and 17 that have exited. Its top competitors include companies like Drug Farm, LEXEO Therapeutics and Cassava Sciences.
Company Details
Developer of therapeutics for age-related diseases. The company uses propriety technology includes the ALEMBIC that focuses on developing medicines to combat biological aging by targeting pathologic cells like senescent ones that drive age-related diseases.
- Website
- rubedolife.com
- Social
- Email ID
- *****@rubedolife.com
- Registered Address
- Sunnyvale, California
Key Metrics
Founded Year
2018
Location
Sunnyvale, United States
Stage
Series A
Total Funding
$52M in 2 rounds
Latest Funding Round
Investors
Ranked
3rd among 161 active competitors
Employee Count
32 as on Jul 31, 2026
Legal entities associated with RUBEDO LIFE SCIENCES
RUBEDO LIFE SCIENCES is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Rubedo Life Sciences, Inc. CIN: 824352074 , United States, Active | Dec 31, 1999 | - | 28 (As on Dec 31, 2024) | - |
Sign up to download RUBEDO LIFE SCIENCES's company profile
RUBEDO LIFE SCIENCES's funding and investors
RUBEDO LIFE SCIENCES has raised a total funding of $52M over 2 rounds. Its first funding round was on Dec 03, 2020. Its latest funding round was a Series A round on Apr 22, 2024 for $*****. 10 investors participated in its latest round. RUBEDO LIFE SCIENCES has 13 institutional investors.
Here is the list of recent funding rounds of RUBEDO LIFE SCIENCES:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Apr 22, 2024 | 6825344 | Series A | 7142417 | 2449446 | 4060027 | 2023597 |
Dec 03, 2020 | 2605441 | Seed | 8987752 | 2734460 |
Access funding benchmarks and valuations. Sign up today!View details of RUBEDO LIFE SCIENCES's funding rounds and investors
RUBEDO LIFE SCIENCES's founders and board of directors
Founder? Claim ProfileThe founders of RUBEDO LIFE SCIENCES are Marco Quarta, Mark Gallop and Julian Klein. Marco Quarta is the CEO of RUBEDO LIFE SCIENCES.
Here are the details of RUBEDO LIFE SCIENCES's key team members:
- Marco Quarta: Co-Founder & CEO of RUBEDO LIFE SCIENCES. Contact Info: 1 email address
- Mark Gallop: Co-Founder of RUBEDO LIFE SCIENCES. Contact Info: 1 email address
- Julian Klein: Co-Founder of RUBEDO LIFE SCIENCES. Contact Info: 1 email address
View details of RUBEDO LIFE SCIENCES's Founder profiles and Board Members
RUBEDO LIFE SCIENCES's employee count trend
RUBEDO LIFE SCIENCES has 32 employees as of Jul 26. Here is RUBEDO LIFE SCIENCES's employee count trend over the years:
Uncover RUBEDO LIFE SCIENCES's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
RUBEDO LIFE SCIENCES's Competitors and alternates
Top competitors of RUBEDO LIFE SCIENCES include Drug Farm, LEXEO Therapeutics and Cassava Sciences. Here is the list of Top 10 competitors of RUBEDO LIFE SCIENCES, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Developer of a novel treatment for metabolic diseases | $138M | 64/100 | ||
2nd |  LEXEO Therapeutics 2018, New York City (United States), Public | Developer of gene therapy for the treatment of CLN2 Batten and Alzheimer's diseases | $185M | 61/100 | |
3rd |  RUBEDO LIFE SCIENCES 2018, Sunnyvale (United States), Series A | Developer of therapeutics for age-related diseases | $52M | 61/100 | |
4th | Cassava Sciences 1998, Austin (United States), Public | Developer of small molecule-based therapeutic solutions for treating neurological diseases | - | 59/100 | |
5th | Acumen Pharmaceuticals 1996, Livermore (United States), Public | Developer of monoclonal antibody therapeutics for Alzheimer's disease | $2.2M | 56/100 | |
6th | Developer of devices for neurodegenerative diseases | $25.2M | 56/100 | ||
7th | Alzheon 2013, Framingham (United States), Series E | Developer of disease-modifying treatments for Alzheimer's disease and other neurodegenerative disorders | $195M | 56/100 | |
8th |  OncoC4 2020, Rockville (United States), Series B | Developer of immunotherapy for cancer patients | $50M | 56/100 | |
9th | Developer of medical food and drugs for Alzheimer's disease | $255M | 56/100 | ||
10th | _1574834265256.png?devicePixelRatio=2&height=30&width=30){kind=logo} Shaperon 2008, Seoul (South Korea), Public | Developer of therapies for multiple diseases | - | 56/100 |
_1547206285034.png?devicePixelRatio=2&height=30&width=30){kind=logo}
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on RUBEDO LIFE SCIENCES's competitors? Click here to see the top ones
RUBEDO LIFE SCIENCES's Investments and acquisitions
RUBEDO LIFE SCIENCES has made no investments or acquisitions yet.
Reports related to RUBEDO LIFE SCIENCES
Here is the latest report on RUBEDO LIFE SCIENCES's sector:
News related to RUBEDO LIFE SCIENCES
Filter this listMedia has covered RUBEDO LIFE SCIENCES for a total of 6 events in the last 1 year, 3 of them have been about company updates and 1 about partnerships.
•
•
Rubedo Life Sciences Announces Phase 1 Trial Results for RLS-1496Business Wire•Mar 26, 2026•RUBEDO LIFE SCIENCES
•
Rubedo Life Sciences and SVAX Announce Strategic Partnership During FII Week in RiyadhBusiness Wire•Oct 30, 2025•Saudi Vax, RUBEDO LIFE SCIENCES
•
Rubedo Life Sciences Receives FDA Clearance for RLS-1496 IND, Expands Advisory BoardKorea Newswire•Sep 18, 2025•RUBEDO LIFE SCIENCES
•
Rubedo Life Sciences Starts Phase 1 Trial for Senescent Cell DrugBusiness Wire India•May 22, 2025•RUBEDO LIFE SCIENCES
•
Rubedo's new drug, RLS-1496, begins human trials targeting aging cells.
Financial Post•May 22, 2025•RUBEDO LIFE SCIENCES
•
Rubedo starts Phase 1 trial of RLS-1496, a new drug targeting senescent cells.
Business Wire•May 22, 2025•RUBEDO LIFE SCIENCES
•
Rubedo Life Sciences' Drug Discovery Platform Helps Identify Senescent Neurons in New StudyFinancial Post•May 15, 2025•RUBEDO LIFE SCIENCES
•
Rubedo's aging-cell drug RLS-1496 enters clinical trials.Business Wire•Jan 16, 2025•RUBEDO LIFE SCIENCES
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about RUBEDO LIFE SCIENCES
Explore our recently published companies
- Alfresco - London based, 1996 founded, Unfunded company
- Katana Sports - 2022 founded, Unfunded company
- Anand Rathi - Mumbai based, 1994 founded, Public company
- Providence Health & Services - United States based, 1859 founded, Funding Raised company
- Entekhaabco - Kuwait City based, 2019 founded, Unfunded company
- Glovnetics - Gurugram based, 2022 founded, Unfunded company
